BackTable Inc.

BackTable Tumor Board

Health EN ↓ 93 episodes

BackTable Tumor Board is a multi-disciplinary podcast for healthcare professionals that play an active role in cancer care.

Be sure to visit the podcast's website and support the creator: www.backtable.com

Author

BackTable Inc.

Category

Health

Podcast website

www.backtable.com

Latest episode

Nov 19, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Ep. 93 From Neoadjuvant and Perioperative Therapy to Surgery: Multidisciplinary Decisions in Early Stage NSCLC with Dr. John Lazar 19.11.2026

“If I have a complete pathological response, why do I need to get surgery?” It is one of the hottest questions in early-stage non-small cell lung cancer (NSCLC), and Dr. John Lazar hears it from his patients after neoadjuvant therapy. On this episode of the BackTable Lung Cancer Creator Weekend™, medical oncologist Dr. Kate Baker talks with Dr. Lazar, thoracic surgeon at Ascension Saint Thomas, ab...

Ep. 92 Multidisciplinary Approaches in Pancreatic Cancer Care with Dr. Arsen Osipov and Dr. Adam Yopp 17.11.2026

At Cedars-Sinai, the time from a pancreatic cancer diagnosis to the first dose of chemotherapy fell from about a month to 14 days, and trial enrollment nearly tripled, once every specialist started seeing the patient in the same room on the same day. On this episode of the BackTable GI Oncology Creator Weekend™, medical oncologist Dr. Andrew Hendifar of Cedars-Sinai is joined by surgical oncologis...

Ep. 91 Direct Contracting in Healthcare with Mark Cuban 12.11.2026

"No cancer patient ever got healthier because their claim was denied and delayed," Mark Cuban says, and his answer is a contract that starts by trusting the doctor. On this episode of the BackTable Podcast, Dr. Ruchika Talwar, value-based care leader at Vanderbilt University Medical Center, talks with Mark Cuban, entrepreneur and founder of Mark Cuban Cost Plus Drug Company, about who actually set...

Ep. 90 Metastatic Pancreatic Cancer: A New Era of Treatment? with Dr. Arsen Osipov and Dr. Daniel Ahn 10.11.2026

A drug that nearly doubles overall survival in metastatic pancreatic cancer is something Dr. Arsen Osipov says the field has never seen before, and it is why he calls the pan-RAS inhibitor daraxonrasib a paradigm shift on the scale of the first immunotherapy approvals. On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Andrew Hendifar leads a tumor board on metastatic pancreat...

Ep. 89 Perioperative Management of Pancreatic Cancer with Dr. Arsen Osipov and Dr. Daniel Ahn 03.11.2026

Most patients with localized pancreatic cancer already have disease the scans cannot see, which is why these GI oncologists treat chemotherapy before surgery as a test of tumor biology. On this episode of the BackTable GI Oncology Creator Weekend™, medical oncologist Dr. Andrew Hendifar leads a tumor board with GI medical oncologists Dr. Arsen Osipov and Dr. Daniel Ahn on the perioperative managem...

Ep. 88 Beyond First-Line Therapy: Treatment Strategies for Advanced Neuroendocrine Tumors with Dr. Mark Lewis 30.10.2026

Few oncologists know neuroendocrine tumors from both sides of the exam table: first as a patient diagnosed during training, and now as the doctor treating them. This physician brings both perspectives to one pressing question: when a tumor progresses on a somatostatin analog, what comes next? On this episode of BackTable Tumor Board, Dr. Aman Chauhan, a medical oncologist at UCSF, interviews Dr. M...

Ep. 87 Diagnosis & Management of Advanced HER2-Negative Upper GI Cancers with Dr. Ronan Hsieh and Dr. Dani Castillo 27.10.2026

Five years ago, first-line treatment for advanced HER2-negative gastroesophageal cancer meant chemotherapy; today claudin 18.2, PD-L1, and mismatch repair status shape the plan, often for a patient who cannot afford to wait for the results. On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews medical oncologists Dr. Ronan Hsieh and Dr. Dani Castillo about t...

Ep. 86 Optimizing Treatment for Advanced HER2-Positive Upper GI Cancers with Dr. Geoffrey Buckle and Dr. Ronan Hsieh 20.10.2026

When a gastroesophageal tumor is positive for HER2, PD-L1, and claudin 18.2, which target should you treat first and how do you decide? On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews Dr. Geoffrey Buckle, a GI medical oncologist at UCSF, and Dr. Ronan Hsieh, a GI oncologist at Swedish Cancer Institute in Seattle, for a breakdown of therapy selection an...

Ep. 85 Perioperative Management in Upper GI Cancers with Dr. Dani Castillo and Dr. Alexandra Gangi 13.10.2026

How do you choose between perioperative chemotherapy and trimodality therapy for a patient with localized upper GI cancer, and what has the newest data actually settled? On this episode of BackTable Tumor Board, host Dr. Kate Baker interviews Dr. Dani Castillo, a medical oncologist at City of Hope in Duarte, California, and Dr. Alexandra Gangi, a gastrointestinal surgical oncologist at Cedars-Sina...

Ep. 84 Managing Refractory MSS-MCRC: Advanced Treatment Strategies with Dr. Ibrahim Sahin and Dr. Sandra Algaze 06.10.2026

What options remain when a patient with microsatellite stable metastatic colorectal cancer (MSS mCRC) has progressed through every standard line of chemotherapy? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Sandra Algaze to explore the nuances of late-line management in MSS-mCRC. They discuss how to approach oxaliplatin retreatment and anti-EGFR rec...

Ep. 83 Molecular-Driven Therapies in Colorectal Cancer with Dr. Ibrahim Sahin and Dr. Sandra Algaze 29.09.2026

Which molecular alterations in colorectal cancer now change treatment and how quickly do you need the results to make the right call? On this episode of BackTable Tumor Board, Dr. Jun Gong interviews Dr. Ibrahim Sahin and Dr. Sandra Algaze about the latest advances in molecular-driven therapy across adjuvant and metastatic settings. They cover aspirin in PI3K-altered disease, the shift toward earl...

Ep. 82 Advances in Perioperative Colorectal Cancer Management with Dr. Ibrahim Sahin and Dr. Alexandra Gangi 22.09.2026

How much of perioperative colorectal cancer management has changed in just one year, and what does it mean for patient care? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Alexandra Gangi to review the latest practice-changing data in colon and rectal cancer. They discuss observation versus maintenance immunotherapy in MSI-high disease, the CHALLENGE...

Ep. 81 CNS Disease in Breast Cancer: Clinical Management & Strategies with Dr. Barbara O'Brien 15.09.2026

How should a breast cancer team manage central nervous system (CNS) disease now that systemic therapy, radiation, and surgery all compete for the first move? On this episode of BackTable Tumor Board, host Dr. Lindsay Peterson interviews Dr. Barbara O'Brien, neuro-oncologist at MD Anderson, about diagnosis, sequencing, and follow-up for CNS disease in breast cancer. They discuss risk by subtype, wh...

Ep. 80 Scaling Community CAR-T: Operational Lessons and Future Directions with Dr. Mike Byrne 08.09.2026

How does delivering CAR-T in the community change patient care, and what has to happen next for these programs to scale? On this episode of the BackTable Tumor Board Podcast, host Aaron Lyss interviews Dr. Mike Byrne, hematologist at Tennessee Oncology and medical director for cellular therapy at OneOncology, about operational lessons and future directions for outpatient CAR-T therapy. They discus...

Ep. 79 Gynecologic Cancer Surveillance: Best Practices & Updates with Dr. Ritu Salani 01.09.2026

Does catching cancer earlier with surveillance always translate to better outcomes for gynecologic cancer patients? On this episode of BackTable Women’s Health, hosts Dr. Mona Guo and Dr. Marcia Ciccone interview Dr. Ritu Salani, Professor of OBGYN at UCLA and lead author of the updated SGO surveillance clinical practice statements. They discuss how post–curative-intent surveillance has evolved am...

Ep. 78 Developing CAR T-cell Programs in Community Oncology with Dr. Mike Byrne 25.08.2026

Where does access to cell therapy actually break down, and can community practices close the gap? On this episode of BackTable Tumor Board, host Aaron Lyss interviews Dr. Mike Byrne, a hematologist at Tennessee Oncology, about the challenges and successes of building an outpatient CAR T program in the community setting. They discuss the critical stakeholder relationships, operational and financial...

Ep. 77 AI's Impact on Oncology Practice with Dr. Larry Bilbrey 18.08.2026

Where is AI already making oncology practice more efficient, and where does human expertise remain irreplaceable? In this episode of BackTable Tumor Board, medical oncologists Dr. Kate Baker and Dr. Larry Bilbrey discuss how AI is improving oncology workflow, such as scribing and information retrieval, but is far from replacing clinicians, especially for hands-on care. --- Get the BackTable apphtt...

Ep. 76 GU Oncology: ASCO Highlights & Impacts on Practice with Dr. Alan Tan 11.08.2026

Is GU oncology entering a new era of early intensification and precision therapy? On this episode of the BackTable Tumor Board Podcast, Dr. Katy Beckermann and Dr. Alan Tan break down the latest GU oncology highlights from ASCO, including key updates in prostate, renal cell, and urothelial carcinoma. They discuss new data supporting HRR/BRCA-focused therapy in HSPC, the importance of early biomark...

Ep. 75 Applying CheckMate 8HW: Practical Updates for MSI-High CRC with Dr. Cathy Eng 04.08.2026

Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical oncologist Jun Gong interviews Dr. Cathy Eng about updates from the phase III CheckMate-8HW trial in centrally confirmed MSI-high/dMMR metastatic colorectal cancer, comparing nivolumab/ipilimumab, nivolumab, and chemotherapy. They discuss initial findings demonstrating i...

Ep. 74 Systemic Therapy Strategies for Treating Neuroendocrine Tumors with Dr. Chih-Yi "Andy" Liao and Dr. Robert Ramirez 28.07.2026

What first-line therapies should be considered for patients with higher-grade, metastatic neuroendocrine tumors (NETs)? In this new episode of BackTable Tumor Board, Drs. Lingling Du, Chih-Yi Liao, and Robert Ramirez discuss the use of systemic or radioligand therapies for metastatic well-differentiated NETs. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by N...

Ep. 73 Comprehensive Care in Breast Cancer Survivorship with Dr. Lindsay Peterson 21.07.2026

When breast cancer treatment ends, recurrence surveillance can easily overshadow the symptoms and concerns that continue to affect daily life. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Lindsay Peterson discuss how effective survivorship care can address recurrence anxiety, endocrine therapy toxicities, bone health, sexual health, and the broader emotional and pra...

Ep. 72 Optimizing Liver-Directed Interventions for Neuroendocrine Tumors with Dr. Chih-Yi "Andy" Liao and Dr. Abdul Khan 14.07.2026

What factors come into play when deciding whether to use liver-directed therapy or systemic therapies for neuroendocrine tumors? In this episode of the BackTable Tumor Board Podcast, Dr. Lingling Du, Dr. Chih-Yi Liao, and Dr. Abdul Khan discuss the structure of a multidisciplinary tumor board and how they approach decision-making for patients with neuroendocrine tumors. The conversation explores w...

Ep. 71 Exploring PARP Inhibitor Combinations in Prostate Cancer with Dr. Rana McKay and Dr. Emmanuel Antonarakis 07.07.2026

With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient selection, timing, toxicity, and genetic testing are shaping the use of PARP inhibitor combinations in c...

Ep. 70 Diagnosis & Initial Management of Neuroendocrine Tumors with Dr. Chih-Yi Liao and Dr. Xavier Keutgen 30.06.2026

How do you unravel the complexity of diagnosing and managing neuroendocrine tumors, where every case demands a tailored approach? In this episode of BackTable TumorBoard, host Dr. Lingling Du is joined by Dr. Chih-Yi Liao and Dr. Xavier Keutgen to break down the essential steps from first symptoms to staging, imaging, and early treatment decisions for NET patients. The discussion covers the spectr...

Ep. 69 Managing Intravesical Therapy Toxicities in Bladder Cancer with Dr. Meredith Donahue and Mary Dunn, NP 25.06.2026

How can clinics minimize toxicity and maximize outcomes in intravesical bladder cancer treatment? In this episode of BackTable Urology, host Dr. Vignesh Packiam talks with nurse practitioners Mary Dunn (UNC) and Meredith Donahue (Vanderbilt) about how advanced practice providers (APP) workflows and hands-on management are transforming care for non-muscle-invasive bladder cancer. The discussion hig...

Listen to the BackTable Tumor Board podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.